Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.

Jin SuminokuraMorikazu MiyamotoTomoyuki YoshikawaHiroko KoutaYoshihiro KikuchiTaira HadaHiroki IshibashiTsubasa ItoHideki IwahashiSoichiro KakimotoRie SuzukiHiroko MatsuuraNaohisa KishimotoMasashi Takano

Published in: BMC cancer (2022)

Weekly low-dose administration of Bev might improve prognosis and decrease the frequency of adverse effects associated with this drug although the prospective study was needed to get corroboration.

Keyphrases

low dose
combination therapy
high dose
drug induced
adverse drug
risk assessment
human health
climate change